HYPERION DEFI, INC. 10-Q

Item 5. Other Information. None. Item 6. Exhibits. ​ ​ ​ ​ ​ ​ ​ Exhibit ​ Incorporated by Reference (Unless Otherwise Indicated) Number ​ Exhibit Description ​ Form File No. Exhibit Filing Date ​ 10.1+ ​ Amendment 1 to the License Agreement between Eyenovia, Inc. and Arctic Vision (Hong Kong) Limited, dated September 14, 2021 ​ — ​ — ​ — ​ Filed herewith ​ 10.2+ ​ Amendment 2 to the Exclusive License Agreement between Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd., effective as of May 2021 ​ — ​ — ​ — ​ Filed herewith ​ 10.3+ ​ First Amendment to Loan and Security Agreement between Eyenovia, Inc. and Silicon Valley Bank, dated September 29, 2021 ​ — ​ — ​ — ​ Filed herewith ​ 31.1 ​ Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 ​ — ​ — ​ — ​ Filed herewith ​ 31.2 ​ Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 ​ — ​ — ​ — ​ Filed herewith ​ 32.1 ​ Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 ​ — ​ — ​ — ​ Filed herewith ​ 32.2 ​ Certification of the Principal Financial and Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 ​ — ​ — ​ — ​ Filed herewith ​ 101 ​ Inline Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Condensed Balance Sheets as of September 30, 2021 and December 31, 2020; (ii) Condensed Statements of Operations for the Three and Nine Months Ended September 30, 2021 and 2020; (iii) Condensed Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended September 30, 2021 and 2020; Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2021 and 2020; and (iv) Notes to Condensed Financial Statements ​ ​ ​ ​ ​ 104 ​ Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ + Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (“[***]”) because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed. ​ ​ 27 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ​ EYENOVIA, INC. November 12, 2021 By: /s/ John Gandolfo John Gandolfo Chief Financial Officer (Principal Financial and Accounting Officer) ​ ​ ​ 28